Ajay Yadlapati1, Christopher Groh2, S Chris Malaisrie3, Mark Gajjar2, Jane Kruse3, Sheridan Meyers2, Rod Passman2. 1. Division of Cardiology, Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, 676 N. St. Clair Street, Suite 600, Chicago, IL, 60611-2996, USA. ajay.yadlapati@gmail.com. 2. Division of Cardiology, Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, 676 N. St. Clair Street, Suite 600, Chicago, IL, 60611-2996, USA. 3. Division of Cardiac Surgery, Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611-2968, USA.
Abstract
PURPOSE: Prosthetic valve replacement is performed in several hundred thousand patients worldwide annually, and many of these patients have or will ultimately develop atrial fibrillation or flutter (AF). Novel oral anticoagulants (NOACs) are not recommended in patients with AF and mechanical valves but have not been evaluated in patients with bioprosthetic valves. This study sought to evaluate the efficacy and safety of NOACs in patients with AF and bioprosthetic valves. METHODS: A retrospective single-center cohort study was performed on all patients with bioprosthetic valve implantation, for whom a NOAC was prescribed for the indication of AF. Patients were evaluated for thromboembolic events including imaging confirmed ischemic stroke, clinically suspected transient ischemic attack, and major bleeding events (according to International Society on Thrombosis and Hemostasis definition). RESULTS: In total, 73 patients (26 female, 35.6 %) were identified. NOAC therapy began, on average, 990.0 ± 1029.1 days after bioprosthetic valve implantation for an average duration of 511.8 ± 400.8 days. Aspirin was used concomitantly in a majority of patients (72.6 %). There were no ischemic strokes identified (0.0 %) and one possible TIA (1.4 %). There were 6 (8.2 %) minor and 5 (6.9 %) major bleeding events. CONCLUSION: The use of NOAC therapy for AF in patients with bioprosthetic valves appears safe and effective in the occurrence of thromboembolic events, however, at the expense of increased bleeding. Larger studies are necessary to confirm these findings.
PURPOSE: Prosthetic valve replacement is performed in several hundred thousand patients worldwide annually, and many of these patients have or will ultimately develop atrial fibrillation or flutter (AF). Novel oral anticoagulants (NOACs) are not recommended in patients with AF and mechanical valves but have not been evaluated in patients with bioprosthetic valves. This study sought to evaluate the efficacy and safety of NOACs in patients with AF and bioprosthetic valves. METHODS: A retrospective single-center cohort study was performed on all patients with bioprosthetic valve implantation, for whom a NOAC was prescribed for the indication of AF. Patients were evaluated for thromboembolic events including imaging confirmed ischemic stroke, clinically suspected transient ischemic attack, and major bleeding events (according to International Society on Thrombosis and Hemostasis definition). RESULTS: In total, 73 patients (26 female, 35.6 %) were identified. NOAC therapy began, on average, 990.0 ± 1029.1 days after bioprosthetic valve implantation for an average duration of 511.8 ± 400.8 days. Aspirin was used concomitantly in a majority of patients (72.6 %). There were no ischemic strokes identified (0.0 %) and one possible TIA (1.4 %). There were 6 (8.2 %) minor and 5 (6.9 %) major bleeding events. CONCLUSION: The use of NOAC therapy for AF in patients with bioprosthetic valves appears safe and effective in the occurrence of thromboembolic events, however, at the expense of increased bleeding. Larger studies are necessary to confirm these findings.
Authors: W R Jamieson; H Ling; L H Burr; G J Fradet; R T Miyagishima; M T Janusz; S V Lichtenstein Journal: Ann Thorac Surg Date: 1998-12 Impact factor: 4.330
Authors: Susan Colilla; Ann Crow; William Petkun; Daniel E Singer; Teresa Simon; Xianchen Liu Journal: Am J Cardiol Date: 2013-07-04 Impact factor: 2.778
Authors: M Heras; J H Chesebro; V Fuster; W J Penny; D E Grill; K R Bailey; G K Danielson; T A Orszulak; J R Pluth; F J Puga Journal: J Am Coll Cardiol Date: 1995-04 Impact factor: 24.094
Authors: T Steiner; M Böhm; M Dichgans; H-C Diener; C Ell; M Endres; C Epple; M Grond; U Laufs; G Nickenig; H Riess; J Röther; P D Schellinger; M Spannagl; R Veltkamp Journal: Clin Res Cardiol Date: 2013-05-14 Impact factor: 5.460
Authors: Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman Journal: N Engl J Med Date: 2013-11-19 Impact factor: 91.245
Authors: Sally Tamayo; W Frank Peacock; Manesh Patel; Nicholas Sicignano; Kathleen P Hopf; Larry E Fields; Troy Sarich; Shujian Wu; Daniel Yannicelli; Zhong Yuan Journal: Clin Cardiol Date: 2015-01-14 Impact factor: 2.882
Authors: Jared P Beller; Elizabeth D Krebs; Robert B Hawkins; J Hunter Mehaffey; Mohammed A Quader; Alan M Speir; Andy C Kiser; Mark Joseph; Leora T Yarboro; Nicholas R Teman; Gorav Ailawadi Journal: J Thorac Cardiovasc Surg Date: 2019-09-28 Impact factor: 5.209
Authors: Nicolas A Geis; Christina Kiriakou; Emmanuel Chorianopoulos; Lorenz Uhlmann; Hugo A Katus; Raffi Bekeredjian Journal: Clin Res Cardiol Date: 2018-04-11 Impact factor: 5.460
Authors: Dan Liu; Kai Hu; Marie Schmidt; Jonas Müntze; Octavian Maniuc; Daniel Gensler; Daniel Oder; Tim Salinger; Frank Weidemann; Georg Ertl; Stefan Frantz; Christoph Wanner; Peter Nordbeck Journal: Clin Res Cardiol Date: 2018-05-24 Impact factor: 5.460